With the „Schwerin 2“ project, Ypsomed is expanding its production capacities for medical technology products in Germany. The company is investing more than half a billion Swiss francs and creating over 650 new jobs in two construction phases.
The Swiss medical technology manufacturer Ypsomed has heralded the construction of its second production plant in Schwerin with a ceremonial laying of the foundation stone. According to the company, the „Schwerin 2“ project is a response to the growing global demand for self-medication solutions - particularly in the areas of diabetes care and drug administration.
Expansion in two phases
Construction work on the first stage began in January 2025. New production halls, an administration building, a fully automated high-bay warehouse and a technology centre are being built on a total of 37,000 square metres. The second expansion stage will add a further 17,000 square metres of production space to the site. The total investment amounts to over 500 million Swiss francs.
Focus on sustainability
Ypsomed has opted for sustainable construction in accordance with the internationally recognised LEED Gold standard (Leadership in Energy and Environmental Design). The production roofs will be fully equipped with photovoltaic systems. There are also plans to install a wind turbine to generate its own electricity.
New jobs and apprenticeships
The first construction phase will create around 350 new jobs and 20 additional apprenticeships. A further 300 jobs and 15 apprenticeships will be added in the second phase. This will bring the total number of employees at the site to over 1,000.
Part of global growth strategy
The expansion in Schwerin is part of Ypsomed's global growth strategy. The company will open its first own production facility in Changzhou, China, at the end of June 2025. A suitable location is currently being evaluated in the USA. In Switzerland, capacities at the Burgdorf and Solothurn sites will also be further expanded.
Source: Ypsomed
